RYBELSUS
PeakNDAORALTABLET
Approved
Jan 2020
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
RYBELSUS by Novo Nordisk is glp-1 analogue with 94% sequence homology to human glp-1. First approved in 2020.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RYBELSUS is an oral formulation of semaglutide, a GLP-1 receptor agonist with 94% sequence homology to native human GLP-1. It treats type 2 diabetes by stimulating insulin secretion and inhibiting glucagon secretion in a glucose-dependent manner, with a long half-life sustained through albumin binding and DPP-4 protection. The mechanism also involves a minor delay in gastric emptying.
Peak
Peak lifecycle status indicates a mature, stable commercial organization with established market presence and team consolidation opportunities.
Mechanism of Action
GLP-1 analogue with 94% sequence homology to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1. GLP-1 is a physiological hormone that has multiple actions on glucose, mediated by the GLP-1 receptors. The…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes
Started May 2026
478 enrolled
Type 2 Diabetes
Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
Started Dec 2025
600 enrolled
Diabetes Mellitus, Type 2
Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD)
Started Jan 2024
50 enrolled
Alcohol Use Disorder
Trial to Learn About the Study Medicine (PF-07081532) and Rybelsus in People With Type 2 Diabetes and Separately PF-07081532 in People With Obesity
Started Oct 2022
902 enrolled
Diabetes MellitusObesity
A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
Started Sep 2021
1,020 enrolled
Diabetes Mellitus, Type 2
Worked on RYBELSUS at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.